Individualizing hormone therapy: Weighing risks and benefits

Article

As women transition into menopause, they may wish to have hormone therapy. Find out what the risks and benefits of the therapy are.

Age at HT initiation

HT dosage

A second important influence on the HT risk-benefit profile is the dose of estrogen and progestin. Evidence is substantial that low-dose HT is effective in preventing bone loss and treating menopausal symptoms with less bleeding and other side effects than higher doses.12-14 More important, lower doses are also associated with lower risks.

The Nurses' Health Study (NHS) was a prospective, observational cohort study of 70,533 postmenopausal women that investigated duration, dose, and type of HT in preventing cardiovascular disease (CVD) over 20 years of follow-up. Investigators found that an estrogen dose of 0.3 mg/day was associated with a statistically significant lower risk of both major CVD and stroke, whereas higher doses were associated with an increased risk of stroke but reduced risk of CVD. (Table 2).15

Recent Videos
The significance of the Supreme Court upholding mifepristone access | Image Credit: unchealth.org
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
raanan meyer, md
© 2024 MJH Life Sciences

All rights reserved.